Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines

One of the main goals of the Cancer Dependency Map project is to systematically identify cancer vulnerabilities across cancer types to accelerate therapeutic discovery. Project Achilles serves this goal through the in vitro study of genetic dependencies in cancer cell lines using CRISPR/Cas9 (and, previously, RNAi) loss-of-function screens. The project is committed to the public release of its experimental results quarterly on the DepMap Portal (https://depmap.org), on a pre-publication basis. As the experiment has evolved, data processing procedures have changed. Here we present the current and projected Achilles processing pipeline, including recent improvements and the analyses that led us to adopt them, spanning data releases from early 2018 to the first quarter of 2020. Notable changes include quality control metrics, calculation of probabilities of dependency, and correction for screen quality and other biases. Developing and improving methods for extracting biologically-meaningful scores from Achilles experiments is an ongoing process, and we will continue to evaluate and revise data processing procedures to produce the best results.

[1]  Terence P. Speed,et al.  Correcting gene expression data when neither the unwanted variation nor the factor of interest are observed , 2012, Biostatistics.

[2]  E. Hovig,et al.  Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses , 2015, Biostatistics.

[3]  T. Golub,et al.  Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. , 2016, Cancer discovery.

[4]  Aviad Tsherniak,et al.  Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration , 2018, Nature Communications.

[5]  G. Superti-Furga,et al.  Gene essentiality and synthetic lethality in haploid human cells , 2015, Science.

[6]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[7]  Aviad Tsherniak,et al.  Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. , 2018, Cell systems.

[8]  Funda Meric-Bernstam,et al.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Durocher,et al.  High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.

[10]  James M. McFarland,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, bioRxiv.

[11]  Joshua M. Dempster,et al.  Genetic and transcriptional evolution alters cancer cell line drug response , 2018, Nature.

[12]  J. Pritchard,et al.  High‐resolution mapping of cancer cell networks using co‐functional interactions , 2018, bioRxiv.

[13]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[14]  P. Pourquier,et al.  [Genetic and transcriptional evolution alters cancer cell line drug response]. , 2018, Bulletin du cancer.

[15]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[16]  J. Moffat,et al.  Measuring error rates in genomic perturbation screens: gold standards for human functional genomics , 2014, bioRxiv.

[17]  Scott E. Martin,et al.  Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens , 2019, Genome Biology.